Intrinsic value of Diplomat Pharmacy - DPLO

Previous Close

$19.05

  Intrinsic Value

$18.21

stock screener

  Rating & Target

hold

-4%

Previous close

$19.05

 
Intrinsic value

$18.21

 
Up/down potential

-4%

 
Rating

hold

We calculate the intrinsic value of DPLO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  4,575
  4,680
  4,800
  4,935
  5,085
  5,249
  5,428
  5,621
  5,830
  6,053
  6,293
  6,548
  6,820
  7,109
  7,416
  7,741
  8,085
  8,449
  8,833
  9,239
  9,667
  10,119
  10,595
  11,096
  11,625
  12,181
  12,766
  13,382
  14,030
  14,712
Variable operating expenses, $m
  4,522
  4,623
  4,739
  4,868
  5,012
  5,170
  5,342
  5,527
  5,728
  5,943
  6,047
  6,292
  6,553
  6,831
  7,126
  7,438
  7,769
  8,118
  8,487
  8,877
  9,289
  9,723
  10,180
  10,662
  11,170
  11,704
  12,267
  12,859
  13,482
  14,137
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  4,522
  4,623
  4,739
  4,868
  5,012
  5,170
  5,342
  5,527
  5,728
  5,943
  6,047
  6,292
  6,553
  6,831
  7,126
  7,438
  7,769
  8,118
  8,487
  8,877
  9,289
  9,723
  10,180
  10,662
  11,170
  11,704
  12,267
  12,859
  13,482
  14,137
Operating income, $m
  53
  57
  62
  67
  73
  79
  86
  94
  102
  111
  246
  256
  267
  278
  290
  303
  316
  330
  346
  361
  378
  396
  414
  434
  455
  476
  499
  523
  549
  575
EBITDA, $m
  275
  281
  289
  297
  306
  316
  326
  338
  350
  364
  378
  394
  410
  427
  446
  465
  486
  508
  531
  555
  581
  608
  637
  667
  699
  732
  767
  804
  843
  884
Interest expense (income), $m
  5
  39
  40
  42
  44
  45
  48
  50
  53
  55
  58
  61
  65
  69
  72
  77
  81
  86
  91
  96
  101
  107
  113
  120
  127
  134
  141
  149
  158
  167
  176
Earnings before tax, $m
  14
  17
  20
  23
  27
  32
  36
  41
  47
  52
  185
  191
  198
  206
  213
  222
  231
  240
  250
  260
  271
  282
  295
  307
  321
  335
  350
  366
  382
  400
Tax expense, $m
  4
  5
  5
  6
  7
  9
  10
  11
  13
  14
  50
  52
  54
  56
  58
  60
  62
  65
  67
  70
  73
  76
  80
  83
  87
  90
  94
  99
  103
  108
Net income, $m
  10
  12
  15
  17
  20
  23
  26
  30
  34
  38
  135
  140
  145
  150
  156
  162
  168
  175
  182
  190
  198
  206
  215
  224
  234
  245
  255
  267
  279
  292

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,980
  2,025
  2,077
  2,136
  2,200
  2,271
  2,349
  2,432
  2,523
  2,619
  2,723
  2,834
  2,951
  3,076
  3,209
  3,350
  3,498
  3,656
  3,822
  3,998
  4,183
  4,379
  4,584
  4,802
  5,030
  5,271
  5,524
  5,791
  6,071
  6,366
Adjusted assets (=assets-cash), $m
  1,980
  2,025
  2,077
  2,136
  2,200
  2,271
  2,349
  2,432
  2,523
  2,619
  2,723
  2,834
  2,951
  3,076
  3,209
  3,350
  3,498
  3,656
  3,822
  3,998
  4,183
  4,379
  4,584
  4,802
  5,030
  5,271
  5,524
  5,791
  6,071
  6,366
Revenue / Adjusted assets
  2.311
  2.311
  2.311
  2.310
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
Average production assets, $m
  961
  983
  1,008
  1,036
  1,068
  1,102
  1,140
  1,180
  1,224
  1,271
  1,321
  1,375
  1,432
  1,493
  1,557
  1,626
  1,698
  1,774
  1,855
  1,940
  2,030
  2,125
  2,225
  2,330
  2,441
  2,558
  2,681
  2,810
  2,946
  3,090
Working capital, $m
  -210
  -215
  -221
  -227
  -234
  -241
  -250
  -259
  -268
  -278
  -289
  -301
  -314
  -327
  -341
  -356
  -372
  -389
  -406
  -425
  -445
  -465
  -487
  -510
  -535
  -560
  -587
  -616
  -645
  -677
Total debt, $m
  746
  774
  806
  842
  881
  925
  973
  1,024
  1,079
  1,139
  1,202
  1,270
  1,342
  1,419
  1,501
  1,587
  1,678
  1,775
  1,877
  1,985
  2,099
  2,219
  2,345
  2,479
  2,619
  2,767
  2,922
  3,086
  3,258
  3,439
Total liabilities, $m
  1,215
  1,243
  1,275
  1,311
  1,351
  1,395
  1,442
  1,493
  1,549
  1,608
  1,672
  1,740
  1,812
  1,889
  1,970
  2,057
  2,148
  2,245
  2,347
  2,455
  2,568
  2,688
  2,815
  2,948
  3,088
  3,236
  3,392
  3,555
  3,728
  3,909
Total equity, $m
  764
  782
  802
  824
  849
  877
  907
  939
  974
  1,011
  1,051
  1,094
  1,139
  1,187
  1,239
  1,293
  1,350
  1,411
  1,475
  1,543
  1,615
  1,690
  1,770
  1,853
  1,942
  2,035
  2,132
  2,235
  2,343
  2,457
Total liabilities and equity, $m
  1,979
  2,025
  2,077
  2,135
  2,200
  2,272
  2,349
  2,432
  2,523
  2,619
  2,723
  2,834
  2,951
  3,076
  3,209
  3,350
  3,498
  3,656
  3,822
  3,998
  4,183
  4,378
  4,585
  4,801
  5,030
  5,271
  5,524
  5,790
  6,071
  6,366
Debt-to-equity ratio
  0.980
  0.990
  1.000
  1.020
  1.040
  1.060
  1.070
  1.090
  1.110
  1.130
  1.140
  1.160
  1.180
  1.200
  1.210
  1.230
  1.240
  1.260
  1.270
  1.290
  1.300
  1.310
  1.330
  1.340
  1.350
  1.360
  1.370
  1.380
  1.390
  1.400
Adjusted equity ratio
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  10
  12
  15
  17
  20
  23
  26
  30
  34
  38
  135
  140
  145
  150
  156
  162
  168
  175
  182
  190
  198
  206
  215
  224
  234
  245
  255
  267
  279
  292
Depreciation, amort., depletion, $m
  222
  224
  227
  230
  233
  236
  240
  244
  249
  253
  132
  138
  143
  149
  156
  163
  170
  177
  185
  194
  203
  212
  222
  233
  244
  256
  268
  281
  295
  309
Funds from operations, $m
  232
  237
  241
  247
  253
  259
  267
  274
  283
  291
  267
  277
  288
  299
  312
  324
  338
  353
  368
  384
  401
  419
  438
  457
  478
  500
  524
  548
  574
  601
Change in working capital, $m
  -4
  -5
  -6
  -6
  -7
  -8
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -26
  -27
  -28
  -30
  -31
Cash from operations, $m
  236
  241
  247
  253
  260
  267
  275
  283
  292
  302
  278
  289
  300
  313
  326
  339
  354
  369
  385
  402
  420
  439
  459
  480
  503
  526
  550
  576
  603
  632
Maintenance CAPEX, $m
  -94
  -96
  -98
  -101
  -104
  -107
  -110
  -114
  -118
  -122
  -127
  -132
  -138
  -143
  -149
  -156
  -163
  -170
  -177
  -185
  -194
  -203
  -212
  -222
  -233
  -244
  -256
  -268
  -281
  -295
New CAPEX, $m
  -17
  -22
  -25
  -28
  -31
  -34
  -38
  -41
  -44
  -47
  -50
  -54
  -57
  -61
  -64
  -68
  -72
  -76
  -81
  -85
  -90
  -95
  -100
  -105
  -111
  -117
  -123
  -129
  -136
  -143
Cash from investing activities, $m
  -111
  -118
  -123
  -129
  -135
  -141
  -148
  -155
  -162
  -169
  -177
  -186
  -195
  -204
  -213
  -224
  -235
  -246
  -258
  -270
  -284
  -298
  -312
  -327
  -344
  -361
  -379
  -397
  -417
  -438
Free cash flow, $m
  125
  123
  123
  124
  125
  126
  127
  129
  130
  132
  101
  103
  106
  109
  112
  115
  119
  123
  127
  132
  137
  142
  147
  153
  159
  165
  172
  179
  186
  194
Issuance/(repayment) of debt, $m
  25
  28
  32
  36
  40
  44
  47
  51
  55
  59
  64
  68
  72
  77
  81
  86
  91
  97
  102
  108
  114
  120
  126
  133
  140
  148
  156
  164
  172
  181
Issuance/(repurchase) of shares, $m
  4
  5
  6
  5
  5
  4
  3
  2
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  29
  33
  38
  41
  45
  48
  50
  53
  56
  59
  64
  68
  72
  77
  81
  86
  91
  97
  102
  108
  114
  120
  126
  133
  140
  148
  156
  164
  172
  181
Total cash flow (excl. dividends), $m
  154
  157
  161
  165
  169
  174
  178
  182
  186
  192
  164
  171
  178
  186
  193
  202
  211
  220
  229
  240
  250
  262
  273
  286
  299
  313
  327
  343
  358
  375
Retained Cash Flow (-), $m
  -14
  -18
  -20
  -23
  -25
  -27
  -30
  -32
  -35
  -37
  -40
  -43
  -45
  -48
  -51
  -54
  -57
  -61
  -64
  -68
  -72
  -75
  -80
  -84
  -88
  -93
  -98
  -103
  -108
  -114
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  9
  9
  9
  10
  10
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  15
  16
  17
  18
  18
  19
  20
  21
  22
  23
  24
  26
  27
  28
Cash available for distribution, $m
  140
  139
  141
  143
  144
  146
  148
  150
  152
  154
  124
  128
  133
  137
  142
  147
  153
  159
  165
  172
  179
  186
  194
  202
  211
  220
  230
  240
  250
  261
Discount rate, %
  6.00
  6.30
  6.62
  6.95
  7.29
  7.66
  8.04
  8.44
  8.86
  9.31
  9.77
  10.26
  10.78
  11.31
  11.88
  12.47
  13.10
  13.75
  14.44
  15.16
  15.92
  16.72
  17.55
  18.43
  19.35
  20.32
  21.33
  22.40
  23.52
  24.70
PV of cash for distribution, $m
  132
  123
  116
  109
  102
  94
  86
  78
  71
  63
  45
  40
  35
  31
  26
  22
  19
  16
  13
  10
  8
  6
  5
  3
  3
  2
  1
  1
  1
  0
Current shareholders' claim on cash, %
  99.7
  99.3
  98.9
  98.5
  98.1
  97.9
  97.6
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5
  97.5

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company's patient care system is used to coordinate and track patient adherence and safety.

FINANCIAL RATIOS  of  Diplomat Pharmacy (DPLO)

Valuation Ratios
P/E Ratio 45.4
Price to Sales 0.3
Price to Book 2.1
Price to Tangible Book
Price to Cash Flow 41
Price to Free Cash Flow 106
Growth Rates
Sales Growth Rate 31%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 11.8%
Cap. Spend. - 3 Yr. Gr. Rate 25.9%
Financial Strength
Quick Ratio 0
Current Ratio 0
LT Debt to Equity 16.3%
Total Debt to Equity 24%
Interest Coverage 8
Management Effectiveness
Return On Assets 3%
Ret/ On Assets - 3 Yr. Avg. 3%
Return On Total Capital 4%
Ret/ On T. Cap. - 3 Yr. Avg. 5.5%
Return On Equity 5%
Return On Equity - 3 Yr. Avg. 8.1%
Asset Turnover 4.2
Profitability Ratios
Gross Margin 7.4%
Gross Margin - 3 Yr. Avg. 7.2%
EBITDA Margin 2.1%
EBITDA Margin - 3 Yr. Avg. 1.7%
Operating Margin 1.1%
Oper. Margin - 3 Yr. Avg. 1%
Pre-Tax Margin 0.8%
Pre-Tax Margin - 3 Yr. Avg. 0.8%
Net Profit Margin 0.6%
Net Profit Margin - 3 Yr. Avg. 0.5%
Effective Tax Rate 30.6%
Eff/ Tax Rate - 3 Yr. Avg. 38%
Payout Ratio 0%

DPLO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DPLO stock intrinsic value calculation we used $4485 million for the last fiscal year's total revenue generated by Diplomat Pharmacy. The default revenue input number comes from 2017 income statement of Diplomat Pharmacy. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DPLO stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6%, whose default value for DPLO is calculated based on our internal credit rating of Diplomat Pharmacy, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Diplomat Pharmacy.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DPLO stock the variable cost ratio is equal to 98.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for DPLO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Diplomat Pharmacy.

Corporate tax rate of 27% is the nominal tax rate for Diplomat Pharmacy. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DPLO stock is equal to 0.2%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DPLO are equal to 21%.

Life of production assets of 10 years is the average useful life of capital assets used in Diplomat Pharmacy operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DPLO is equal to -4.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $750 million for Diplomat Pharmacy - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 68 million for Diplomat Pharmacy is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Diplomat Pharmacy at the current share price and the inputted number of shares is $1.3 billion.

RELATED COMPANIES Price Int.Val. Rating
ABC AmerisourceBer 87.72 199.01  str.buy
LCI Lannett 13.50 33.06  str.buy
MCK McKesson 129.38 355.02  str.buy
CAH Cardinal Healt 51.90 169.21  str.buy
WBA Walgreens Boot 69.99 69.31  hold
CVS CVS Health 73.68 120.89  str.buy
PINC Premier 38.37 185.18  str.buy

COMPANY NEWS

▶ Diplomat Pharmaceuticals: 2Q Earnings Snapshot   [04:52PM  Associated Press]
▶ Why Diplomat Pharmacy, Inc. Stock Dropped 10.4% Today   [Jul-20-18 04:24PM  Motley Fool]
▶ Diplomat Pharmacy Integrates With New Leadership   [May-15-18 02:50PM  Motley Fool]
▶ Why Diplomat Pharmacy Stock Jumped Today   [May-10-18 01:05PM  Motley Fool]
▶ Diplomat Pharmacy in Final Stages of CEO Search Process   [May-08-18 07:00AM  PR Newswire]
▶ Diplomat Pharmaceuticals: 1Q Earnings Snapshot   [May-07-18 04:53PM  Associated Press]
▶ Edited Transcript of DPLO presentation 7-Mar-17 9:35pm GMT   [Apr-10-18 11:00AM  Thomson Reuters StreetEvents]
▶ Why Diplomat Pharmacy Sank Today   [03:47PM  Motley Fool]
▶ Diplomat Pharmaceuticals posts 4Q profit   [Feb-26-18 04:57PM  Associated Press]
▶ Diplomat Managing Rising Drug Costs to Support Patients   [Feb-21-18 05:30PM  PR Newswire]
▶ Stocks Flashing Renewed Technical Strength: Diplomat Pharmacy   [Jan-08-18 03:00AM  Investor's Business Daily]
▶ Stocks Flashing Renewed Technical Strength: Diplomat Pharmacy   [Dec-26-17 03:00AM  Investor's Business Daily]
▶ Stocks Flashing Renewed Technical Strength: Diplomat Pharmacy   [03:00AM  Investor's Business Daily]
▶ Stocks To Watch: Diplomat Pharmacy Sees Relative Strength Rating Jump To 83   [Dec-12-17 03:00AM  Investor's Business Daily]
▶ Diplomat Adds Chris Luthin as Executive Vice President   [Dec-11-17 04:15PM  PR Newswire]
▶ Why Diplomat Pharmacy Inc Fell Today   [01:58PM  Motley Fool]
▶ Diplomat Pharmacy Inc. Expands Its Offerings   [Nov-13-17 04:28PM  Motley Fool]
▶ Why Diplomat Pharmacy Inc Fell Today   [Nov-07-17 05:02PM  Motley Fool]
▶ Diplomat Pharmaceuticals posts 3Q profit   [Nov-06-17 04:39PM  Associated Press]
▶ Diplomat Pharmacy Shows Rising Price Performance With Jump To 92 RS Rating   [Nov-03-17 03:00AM  Investor's Business Daily]
▶ Diplomat Selected to Dispense VERZENIO for Breast Cancer   [Oct-10-17 08:00AM  PR Newswire]
▶ Diplomat Acquires 8th Day Software, Names New CIO   [Oct-02-17 04:15PM  PR Newswire]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.